Physician profile
Robert Samuel Aaron
NPI 1962694323
$2,715.36
in general payments reported to CMS, 2019-2025
25 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $104 · 2021: $226 · 2022: $202 · 2023: $464 · 2024: $634 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $381.36 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $359.56 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $322.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.84 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $235.28 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $188.91 | 2019-2025 | Entyvio |
| Celgene Corporation | $99.02 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $94.94 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $89.69 | 2023-2025 | |
| Lilly USA, LLC | $75.61 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $63.21 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $58.34 | 2019-2023 | Ocaliva |
| Boston Scientific Corporation | $53.10 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $46.89 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $43.42 | 2021-2025 | Suflave, Sutab |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $43.15 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $38.29 | 2024-2025 | Bylvay, Iqirvo |
| Novo Nordisk INC | $35.64 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $35.43 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $30.67 | 2019-2023 | Cimzia |
| Shionogi INC | $26.73 | 2019-2020 | |
| Gilead Sciences, INC. | $24.85 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $18.64 | 2022 | |
| Aimmune Therapeutics, INC. | $16.92 | 2024 | |
| Medtronic, INC. | $14.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.